Result Summary for 101468/166
| Protocol ID: | 101468/166 |
| Clinical Study ID: | SKF-101468/166 |
| Official Title: | A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies |
| Phase: | Phase 2 |
| Study Indications or Diseases: |
|
| Generic Name: | ropinirole |
| Trade/Product Name: | requip;requip |
| Approved Drug Label: | http://www.gsk.com/products.html |
| Results Summary: |  Click
here to download result summary. |
| Citations: |
|
The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.
